Open company graph database — free web & API
Login

Susmed Inc.

サスメド株式会社
Ticker
Listed market
TYO
Country
Japan
Employees (non-consolidated)
39
Related companies
16
§01

Basic information

BASIC
Head office
10th Floor, Nihonbashi Honcho Showa-dori Building, 3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo, Japan
Chief executive
Taro Ueno
Capital
99,000,000 JPY
Employees (non-consolidated)
39 people
Employees (consolidated)
Start date
2016-02-23
End date
§02

Websites

1 DOMAINS
§03

Business

4
Development of therapeutic applicationsProvision of a platform for joint development of therapeutic applicationsDevelopment and sale of clinical trial systems utilizing blockchainProvision of medical data analysis and consulting services using statistical analysis and machine learning
§04

Related companies

16 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Kyorin Pharmaceutical Co., Ltd.
Group Customer Alliance
Asuka Pharmaceutical Holdings Inc.
Group Customer
Sawai Pharmaceutical Co., Ltd.
Group
Suzuken Corporation
Group
Nippon Chemifa Co., Ltd.
Group
Simic CMO Co., Ltd.
Group
EPS Holdings Inc.
Group Customer
Shionogi & Co., Ltd.
Group Customer
National University Corporation Tohoku University
Group Customer
Accuris Pharma Co., Ltd.
Group Customer
Japan Society of Nephrology Rehabilitation
Group Customer
Sumitomo Corporation
Group
Heartseed Inc.
Customer
National Center of Neurology and Psychiatry
Customer
Nexera Pharma Inc.
Sosei Group Corporation
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

31 EVENTS

Established Susmed LLC in Bunkyo-ku, TokyoSources

Organizational change to a corporationSources

Started clinical trials for sleep disorder treatment applications at two domestic facilitiesSources

Headquarters relocation (2-11-5 Nihonbashi Life Science Building, Nihonbashi Honcho, Chuo-ku, Tokyo)Sources

Start of DTx development support servicesSources

Provision of machine learning automatic analysis systemSources

Selected for theSources

Head Office Relocation (5th Floor, Nihonbashi Honcho 3-chome Building, 3-8-5 Nihonbashi Honcho, Chuo-ku, Tokyo)Sources

Entered into a capital and business alliance agreement with Suzuken Co., Ltd.Sources

Entered into a capital and business alliance agreement with Sumitomo Corporation and Nippon Chemifa Corporation.Sources

Entered into a capital and business alliance agreement with Sawai Pharmaceutical Co., Ltd.Sources

Entered into a business alliance agreement with CMIC Inc. for the development support of digital therapeutics.Sources

Approval for 'Monitoring Business Substitution Using Blockchain Technology' by the Ministry of Economy, Trade and Industry and the Ministry of Health, Labour and Welfare.Sources

Started joint development of a treatment app for chronic kidney disease patients with Tohoku University and the Japan Kidney Rehabilitation Society.Sources

Entered into a business alliance agreement with EPS Holdings Inc. to improve the efficiency of clinical trial operations using blockchain technology.Sources

Head Office Relocation (10th Floor, Nihonbashi Honcho Showa Street Building, 3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo)Sources

Relocated headquarters to 10th floor, Nihonbashi Honcho Showa-dori Building, 3-7-2 Nihonbashi Honcho, Chuo-ku, TokyoSources

Achieved primary endpoints in domestic verification trial of insomnia disorder treatment appSources

Listed on Tokyo Stock Exchange Mothers MarketSources

Entered into sales partnership agreement with Shionogi & Co., Ltd. regarding insomnia disorder treatment appSources

Transition from Mothers Market to Growth Market due to review of Tokyo Stock Exchange market classificationSources

Initiated research and development on clinical data processing methods and quality assurance to promote data utilization with the National Center of Neurology and PsychiatrySources

Signed a business consignment agreement with Acuris Pharma Inc. for the world's first clinical trial using blockchain technologySources

Signed a contract with Kyorin Pharmaceutical Co., Ltd. for joint research, development, and sales of treatment apps in the otolaryngology fieldSources

Obtained manufacturing and marketing approval for insomnia disorder applicationSources

Signed a basic agreement with Tohoku University to promote the use of real-world data (RWD) of medical devices utilizing blockchain technologySources

Signed a contract with Asuka Pharmaceutical Co., Ltd. for joint research, development, and sales of treatment apps in the obstetrics and gynecology fieldSources

Approved as a designated research institution for scientific research grants by the Ministry of Education, Culture, Sports, Science and TechnologySources

Transitioned to a company with an audit and supervisory committeeSources

Obtained partial approval for manufacturing and sales of insomnia disorder appSources

Insurance coverage for insomnia disorder app approvedSources

§07

News

17 ARTICLES

Web Seminar on Workplace Sleep IssuesSources

On November 27, 2026, we will host a free web seminar featuring Professor Yuji Furuie, a special professor at the University of Tokyo, focusing on workplace sleep issues and solutions. Based on the latest data, we will explain the economic losses caused by sleep problems and health management measures with high return on investment. Target audience includes corporate health management, HR and labor personnel, health insurance association staff, occupational physicians, and public health nurses.

Interview with Taro Ueno Published in Nikkei BiotechSources

An article was published in Nikkei Biotech featuring an interview with Taro Ueno, President and CEO of Sasemed Co., Ltd., about the insomnia treatment app 'Medcle'. The article discusses the company's background in app development and its future outlook.

WIRED features interview with President Taro UenoSources

An interview article featuring Taro Ueno, President and CEO of Sasemed Co., Ltd., was published in WIRED. The article discusses the company’s business and future prospects. Please see the link for details.

Sasemed Exhibits at Summit Held Concurrently with BioJapan 2026Sources

Sasemed Co., Ltd. will exhibit at the "Japan Healthcare Venture Summit 2026", which is held concurrently with BioJapan 2026 at Pacifico Yokohama from October 7-9. Through the matching system, we will accept inquiries about clinical development efficiency support services and therapeutic apps, and will also exchange information at Booth V-09. We look forward to your visit.

Susmed's Insomnia App Medcle Featured in Yomiuri ShimbunSources

Susmed Inc.'s Medcle app for insomnia was featured in the Yomiuri Shimbun. See the linked article for details.

Publication of a dialogue article advertisement between Susmed and Asuka Pharmaceutical in Shareholder's HandbookSources

A dialogue article advertisement between Asuka Pharmaceutical Holdings and Susmed has been published in the investment magazine "Shareholder's Handbook." The publication date is September 16, 2026. Details of the article can be checked at the linked source.

World's First Announcement of Drug Manufacturing and Marketing Approval Obtained Using Blockchain TechnologySources

Susmed Inc. announced that it has obtained the world's first drug manufacturing and marketing approval based on clinical trials conducted with the clinical trial system SUSMED SourceDataSync® utilizing blockchain technology. Details can be found in the company's press release.

SusMed President Taro Ueno Interviewed by Nikkei MedicalSources

An interview with President Taro Ueno about Medcle, an app for insomnia disorder, was published in Nikkei Medical on September 4, 2026. See the linked page for details.

Susmed's Medcle Insomnia App Featured in Nikkei MedicalSources

Susmed Inc.'s Medcle app for insomnia was featured in Nikkei Medical. See the linked article for details.

Sumased's Insomnia Disorder App Medcle Featured on NHKSources

On July 23, 2026, NHK NEWS Ohayō Nippon aired a segment featuring Sumased's insomnia disorder app Medcle. It was covered as part of digital healthcare, and details can be confirmed on the official website.

§08

Public records

GOV
National Tax Agency basic information7010003022232
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
サスメド株式会社
Trade name (kana)
サスメド
Name in English
SUSMED, Inc.
Corporation type
301
Address
〒103-0023 東京都中央区日本橋本町3丁目7番2号
Postal code
1030023
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
Tokyo
City in English
3-7-2, Nihonbashi-Honcho, Chuo ku
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2024-10-23
Change date
2021-10-21
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
1
Trade name image ID
Address image ID
Sequence number
2181940
METI gBizINFO7010003022232
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
7010003022232
Trade name
サスメド株式会社
Trade name (kana)
サスメド
Trade name (alphabet)
SUSMED, Inc.
Registry closure date
Reason for registry closure
Registered address
東京都中央区日本橋本町1丁目9番3号
Postal code
1030023
Prefecture
東京都
Prefecture code
13
City or district
中央区
City code
102
Street address
日本橋本町1丁目9番3号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長 上野 太郎
Capital
10000000
Employees
50
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
2015-07-31
Unified government qualification - grade
||C|
Unified government qualification - business items
303|304|306
Update date
2026-09-24
Key information
7010003022232
§09

Sources & updates

SOURCES
↑